Vincerx Pharma Stock to Reverse Split on Tuesday, January 28th (NASDAQ:VINC)

Vincerx Pharma, Inc. (NASDAQ:VINC)’s stock is set to reverse split before the market opens on Tuesday, January 28th. The 1-20 reverse split was announced on Thursday, January 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 27th.

Vincerx Pharma Stock Down 19.4 %

Shares of VINC stock traded down $0.03 during trading on Friday, hitting $0.10. The company had a trading volume of 7,380,350 shares, compared to its average volume of 4,778,677. The stock’s 50-day moving average is $0.22 and its two-hundred day moving average is $0.46. The stock has a market capitalization of $3.50 million, a price-to-earnings ratio of -0.10 and a beta of 1.48. Vincerx Pharma has a 52 week low of $0.10 and a 52 week high of $9.37.

Analysts Set New Price Targets

Separately, Leerink Partners dropped their price objective on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Institutional Trading of Vincerx Pharma

A hedge fund recently bought a new stake in Vincerx Pharma stock. Armistice Capital LLC acquired a new stake in Vincerx Pharma, Inc. (NASDAQ:VINC) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned approximately 6.70% of Vincerx Pharma as of its most recent filing with the SEC. Institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.